Background: There is controversy whether
masked hypertension (
MHT) requires additional intervention. The aim of this study is to evaluate whether
MHT accompanied with high-risk
metabolic syndrome (MetS), as the subphenotype, will have a different prognosis from low-risk MetS. Methods: We applied latent class analysis to identify subphenotypes of
MHT, using the clinical and
biological information collected from High-risk Cardiovascular Factor Screening and
Chronic Disease Management Programme. We modeled the data, examined the relationship between subphenotypes and clinical outcomes, and further explored the impact of
antihypertensive medication. Results: We included a total of 140 patients with
MHT for analysis. The latent class model showed that the two-class (high/low-risk MetS) model was most suitable for
MHT classification. The high-risk MetS subphenotype was characterized by larger waist circumference, lower HDL-C, higher fasting
blood glucose and
triglycerides, and prevalence of diabetes. After four years of follow-up, participants in subphenotype 1 had a higher non-major adverse cardiovascular event (
MACE) survival probability than those in subphenotype 2 (P = 0.016). There was no interaction between different subphenotypes and the use of
antihypertensive medications affecting the occurrence of
MACE. Conclusions: We have identified two subphenotypes in
MHT that have different metabolic characteristics and prognosis, which could give a clue to the importance of tracing the clinical correlation between
MHT and metabolic risk factors. For patients with
MHT and high-risk MetS,
antihypertensive therapy may be insufficient.